Windlas Biotech Ltd.
Fundamentals
- Market cap
- ₹1,630 cr
- P/E
- 24.54×
- ROE
- 12.06%
- Debt / equity
- 0.05
- Div yield
- 0.80%
- 52-week range
- 697.40 — 1097.90
The timeline — 4 notes on Windlas Biotech Ltd.
May 2026
- 22 May 26 · 13:54 IST Brief Brief · Concalls
Windlas Biotech misses Plant 6 timeline as regulatory hit cuts revenue
Regulatory action wiped out the company's codeine syrup business, while geopolitical tension and solvent costs weigh on margins.
- 21 May 26 · 17:39 IST Brief Brief · Earnings
Windlas Biotech’s ₹904 Cr revenue: record, but already priced in.
Q4/FY26 results show 19% revenue growth and 31% PAT growth, but these numbers were disclosed in earlier filings. Real story: 13th consecutive record quarter and Plant-6 on track.
- 21 May 26 · 16:54 IST Brief Brief · Earnings
Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26
Revenue grew 19% to ₹9,041M; profit touched ₹664M. Both numbers were in line with expectations.
- 21 May 26 · 16:34 IST Brief Brief · Earnings
Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30
Revenue grew 19% to ₹9,041 mn, net profit rose 9% to ₹664 mn. Results were widely anticipated with no material surprises.